Costs of breast cancer recurrence after initial treatment for HR+, HER2−, high-risk early breast cancer: estimates from SEER-Medicare linked data

References

• Giaquinto AN, Sung H, Miller KD, et al. Breast cancer statistics, 2022. CA Cancer J Clin. 2022;72(6):524–541. doi: 10.3322/caac.21754.
   PubMed Web of Science ®Google Scholar
• Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5):dju055.
   PubMedGoogle Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323.
   PubMed Web of Science ®Google Scholar
• Howlader N, Cronin KA, Kurian AW, et al. Differences in breast cancer survival by molecular subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018;27(6):619–626. doi: 10.1158/1055-9965.EPI-17-0627.
   PubMed Web of Science ®Google Scholar
• Sheffield KM, Peachey JR, Method M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol. 2022;18(21):2667–2682. doi: 10.2217/fon-2022-0310.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet. 2015;386(10001):1341–1352.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Tang G, Paik S, et al. 21-Gene Recurrence Score for prognosis and prediction of taxane benefit after adjuvant chemotherapy plus endocrine therapy: results from NSABP B-28/NRG Oncology. Breast Cancer Res Treat. 2018;168(1):69–77. doi: 10.1007/s10549-017-4550-8.
   Web of Science ®Google Scholar
• Nitz U, Gluz O, Christgen M, et al. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial. Breast Cancer Res Treat. 2017;165(3):573–583. doi: 10.1007/s10549-017-4358-6.
   PubMed Web of Science ®Google Scholar
• Yamauchi H, Toi M, Takayama S, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. Breast Cancer. 2021;30(4):606–2405. doi: 10.1007/s12282-023-01468-z.
   Google Scholar
• Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021;32(12):1571–1581. doi: 10.1016/j.annonc.2021.10.015.
   PubMed Web of Science ®Google Scholar
• A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). Available from: https://clinicaltrials.gov/ct2/show/NCT05514054.
   Google Scholar
• A study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotherapy in participants with estrogen receptor-positive, HER2-negative early breast cancer (lidERA Breast Cancer). Available from: https://clinicaltrials.gov/ct2/show/NCT04961996.
   Google Scholar
• A study to evaluate the efficacy, safety, and pharmacokinetics of giredestrant plus palbociclib compared with anastrozole plus palbociclib for postmenopausal women with estrogen receptor-positive and HER2-negative untreated early breast cancer (coopERA Breast Cancer). Available from: https://clinicaltrials.gov/ct2/show/NCT04436744.
   Google Scholar
• A trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer (NATALEE). Available from: https://clinicaltrials.gov/ct2/show/NCT03701334.
   Google Scholar
• Stokes ME, Thompson D, Montoya EL, et al. Ten-year survival and cost following breast cancer recurrence: estimates from SEER-medicare data. Value Health. 2008;11(2):213–220. doi: 10.1111/j.1524-4733.2007.00226.x.
   PubMed Web of Science ®Google Scholar
• Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer. 2006;106(9):1875–1882. doi: 10.1002/cncr.21824.
   PubMed Web of Science ®Google Scholar
• Tisdale RL, Ma I, Vail D, et al. Availability of cost-effectiveness studies for drugs with high medicare part D expenditures. JAMA Netw Open. 2021;4(6):e2113969. doi: 10.1001/jamanetworkopen.2021.13969.
   Web of Science ®Google Scholar
• Parts of Medicare. Available from: https://www.ssa.gov/medicare/plan/medicare-parts.
   Google Scholar
• National Cancer Institute. Overview of the SEER program. Available from: https://seer.cancer.gov/about/overview.html.
   Google Scholar
• SEER-Medicaid: brief description of the SEER-medicaid database. Available from: https://healthcaredelivery.cancer.gov/seermedicaid/overview.
   Google Scholar
• Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–99. doi: 10.3322/caac.21388.
   PubMed Web of Science ®Google Scholar
• Warren JL, Mariotto A, Melbert D, et al. Sensitivity of medicare claims to identify cancer recurrence in elderly colorectal and breast cancer patients. Med Care. 2016;54(8):e47–e54. doi: 10.1097/MLR.0000000000000058.
   Web of Science ®Google Scholar
• Hassett MJ, Ritzwoller DP, Taback N, et al. Validating billing/encounter codes as indicators of lung, colorectal, breast, and prostate cancer recurrence using 2 large contemporary cohorts. Med Care. 2014;52(10):e65–e73. doi: 10.1097/MLR.0b013e318277eb6f.
   PubMed Web of Science ®Google Scholar
• Measures that are limited or not available in the data. Available from: https://healthcaredelivery.cancer.gov/seermedicare/considerations/measures.html#8.
   Google Scholar
• Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol. 2007;25(15):2127–2132. doi: 10.1200/JCO.2006.10.3523.
   PubMed Web of Science ®Google Scholar
• Lin DY, Feuer EJ, Etzioni R, et al. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53(2):419–434. doi: 10.2307/2533947.
   PubMed Web of Science ®Google Scholar
• R: A language and environment for statistical computing. Vienna (Austria): R Foundation for Statistical Computing. Available from: https://www.R-project.org/.
   Google Scholar
• Colleoni M, Sun Z, Price KN, et al. Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the international breast cancer study group trials I to V. J Clin Oncol. 2016;34(9):927–935. doi: 10.1200/JCO.2015.62.3504.
   PubMed Web of Science ®Google Scholar
• Cheng L, Swartz MD, Zhao H, et al. Hazard of recurrence among women after primary breast cancer treatment-a 10-year follow-up using data from SEER-Medicare. Cancer Epidemiol Biomarkers Prev. 2012;21(5):800–809. doi: 10.1158/1055-9965.EPI-11-1089.
   Web of Science ®Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi: 10.1200/JCO.20.02514.
   PubMed Web of Science ®Google Scholar
• Sieluk J, Song Y, Freimark J, et al. The economic burden of recurrence in triple-negative breast cancer among working age patients in the United States. Adv Ther. 2022;39(2):943–958. doi: 10.1007/s12325-021-01913-5.
   Web of Science ®Google Scholar
• Mues KE, Liede A, Liu J, et al. Use of the Medicare database in epidemiologic and health services research: a valuable source of real-world evidence on the older and disabled populations in the US. Clin Epidemiol. 2017;9:267–277. doi: 10.2147/CLEP.S105613.
   PubMed Web of Science ®Google Scholar